Congress Materials – Skin of Color Update (SOCU 2024)
2024 Skin of Color Update | Sep 13-15 | New York, NY
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
VISIBLE Cohort A: Guselkumab Demonstrated Skin Clearance Through Week 48 in Participants With Moderate-to-severe Plaque Psoriasis Across All Skin Tones
A. Alexis, A.O. Rodriguez, G. Yadav, S.K. Tyring, O. Choi, T. Alkousakis, D. Chan, T. Ma, M. Sauder, J. Alonso-Llamazares, S.R. Desai
VISIBLE Cohort B: Guselkumab Demonstrated Scalp Clearance Through Week 48 in Participants With Moderate-to-severe Scalp Psoriasis Across All Skin Tones
A. McMichael, T. Bhutani, S. Smith, T. Alkousakis, O. Choi, D. Chan, T. Ma, R. Radusky, J. Yeung, G. Han, S.C. Taylor
VISIBLE: Guselkumab Improves Key Health-Related Quality of Life Measures Through Week 48 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones
Mona Shahriari, Candrice R. Heath, Angela Y. Moore, Jessica Vasquez, Katelyn Rowland, Laura Park-Wyllie, Tony Ma, H. Chih-ho Hong, Lorne Albrecht, Neelam Vashi, Linda Stein Gold
VISIBLE: Guselkumab Pooled Safety Across All Skin Tones Through Week 48
J. Soung, C. Kindred, F. Kerdel, K. Rowland, L. Park-Wyllie, T. Ma, D.N. Adam, R. Radusky, C. Lynde, M. Lee, P. Grimes
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.